Figure 1. Study design for preclinical analyses of intravesical chemotherapy.

Tumor induction was initiated by delivery of Adeno-Cre directly into the bladder lumen of p53^f/f/; Pten^f/f female mice at 8 weeks. Six weeks later (at 14 weeks), mice were imaged using ultrasound (baseline) and then enrolled into one of 8 treatment arms for the preclinical intravesical treatment: vehicle; gemcitabine, docetaxel or cisplatin as single agents, or cisplatin + docetaxel, gemcitabine + docetaxel, or gemcitabine + cisplatin in combination. The treatments were continued for 8 weeks during which time the bladders were imaged every two weeks using ultrasound. At the conclusion of the treatment period (22 weeks) mice were sacrificed for analyses including the endpoints indicated.